World Journal of Urology

, Volume 36, Issue 2, pp 271–276 | Cite as

Safety and feasibility study of holmium laser enucleation of the prostate (HOLEP) on patients receiving dual antiplatelet therapy (DAPT)

  • Jie Sun
  • An Shi
  • Zhen Tong
  • Wei XueEmail author
Original Article



To evaluate the safety and feasibility of Holmium laser enucleation of the prostate (HoLEP) in patients receiving dual antiplatelet therapy (DAPT).


From March 2013 to August 2016, we retrospectively analyzed 1124 benign prostatic hyperplasia (BPH) patients undergoing HoLEP and divided into four groups: 56 cases receiving DAPT therapy (group A); 72 patients treated with continuous single antiplatelet (AP) therapy (group B); 41 patients treated with single AP therapy but intermittent during preoperative time (group C) and 955 cases had no AP therapy (group D). Patients’ baseline characteristics, 1-year clinical outcomes, rates of postoperative bleeding and complications were presented in this study.


All patients received successful operations and no severe postoperative complications occurred. Only one patient in Group D required transfusion. The enucleation time and catheterization time for the DAPT patients were the longest among four groups (p < 0.001, respectively). The overall complications rates within 30 days were 23.2% (13/56) in Group A, 27.8% (20/72) in Group B, 19.5% (8/41) in Group C, and 27.0% (258/955) in Group D, respectively (p = 0.678). By the 12 months, the international prostate symptom scores (IPSS), quality of life scores (QOL) and residual urine volume (RUV) in all groups have been significantly improved.


HoLEP in patients receiving DAPT after coronary artery stunting showed similar results to those achieved in patients receiving single AP therapy or non-AP therapy. It can be a good option, which the urologists can offer to those patients with symptomatic benign prostatic hyperplasia refractory to medical treatment.


Benign prostate hyperplasia Lower urinary tract symptoms Holmium laser enucleation of the prostate Dual antiplatelet therapy 



Benign prostatic hyperplasia


Holmium laser enucleation of the prostate


Transurethral resection of the prostate


Photoselective vaporization of the prostate


Coronary artery bypass grafts


Dual antiplatelet treatment


Prostate-specific antigen


Transrectal ultrasonography


Post-void residual urine



We gratefully acknowledge the urologists making great contributions to the prostatic laser surgery, especially YiRan Huang and Gilling PJ.

Authors’ contributions

SJ: Project development and manuscript writing. SA: Data collection and analysis, and manuscript writing. TZ: Data collection and management. XW: Project development and manuscript editing.


The authors declare that they have no funding.

Compliance with ethical standards

Ethics statement

Institutional Review Board approval of Renji Hospital affiliated to Shanghai JiaoTong University, Medical school was obtained for the retrospective study and patient written informed consent was obtained.

Consent to publish

All of the details can be published and consent for publication was not required for this study.

Availability of data and materials

The datasets during the current study were available from the corresponding author on reasonable request.

Conflict of interest

The authors declare that they have no competing interests.


  1. 1.
    Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314CrossRefPubMedGoogle Scholar
  2. 2.
    Byrne RA, Serruys PW, Baumbach A et al (2015) Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. Eur Heart J 36:2608–2620CrossRefPubMedGoogle Scholar
  3. 3.
    Windecker S, Kolh P, Alfonso F et al (2014) ESC/EACTS guidelines on myocardial revascularization: the task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35:2541–2619CrossRefPubMedGoogle Scholar
  4. 4.
    Banerjee S, Angiolollo DJ, Boden WE et al (2017) Use of anti platelet therapy/DAPT for post-PCI patients undergoing noncardiac surgery. J Am Coll Cardiol 69:1861–1870CrossRefPubMedGoogle Scholar
  5. 5.
    Yu X, Elliott SP, Wilt TJ, McBean AM (2008) Practice patterns in benign prostatic hyperplasia surgical therapy: the dramatic increase in minimally invasive technologies. J Urol 180:241–245CrossRefPubMedGoogle Scholar
  6. 6.
    Pathak RA, Broderick GA, Igel TC et al (2017) Impact of minimally invasive benign prostatic hyperplasia therapies on 30- and 90-Day postoperative office encounters. Urology 99:186–191CrossRefPubMedGoogle Scholar
  7. 7.
    Elshal AM, Mekkawy R, Laymon M et al (2016) Holmium laser enucleation of the prostate for treatment for large-sized benign prostate hyperplasia; is it a realistic endourologic alternative in developing country? World J Urol 34:399–405CrossRefPubMedGoogle Scholar
  8. 8.
    Cynk M (2014) Holmium laser enucleation of the prostate: a review of the clinical trial evidence. Ther Adv Urol 6:62–73CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Mavuduru RM, Mandal AK, Singh SK et al (2009) Comparison of HoLEP and TURP in terms of efficacy in the early postoperative period and perioperative morbidity. Urol Int 82:130–135CrossRefPubMedGoogle Scholar
  10. 10.
    EI Tayeb MM, Jacob JM, Bhojani N, Bammerlin E, Lingeman JE (2016) Holmium laser enucleation of the prostate in patients requiring anticoagulation. J Endourol 30:805–809CrossRefGoogle Scholar
  11. 11.
    Gratzke C, Bachmann A, Descazeaud A et al (2015) EAU guide-lines on the assessment of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 67:1099–1109CrossRefPubMedGoogle Scholar
  12. 12.
    Mamoulakis C, Efthimiou I, Kazoulis S, Christoulaskis I, Sofras F (2011) The modified Clavien classification system: a standardized platform for reporting complications in transurethral resection of the prostate. World J Urol 29:205–210CrossRefPubMedGoogle Scholar
  13. 13.
    Kuo RL, Paterson RF, Kim SC et al (2003) Holmium laser enucleation of the prostate (HoLEP): a technical update. World J Surg Oncol 1:6CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Rassweiler J, Teber D, Kuntz R, Hofmann R (2006) Complications of transurethral resection of the prostate (TURP)—incidence, management, and prevention. Eur Urol 50:969–979CrossRefPubMedGoogle Scholar
  15. 15.
    Descazeaud A, Robert G, Lebdai S et al (2011) Impact of oral anticoagulation on morbidity of transurethral resection of the prostate. World J Urol 29:211–216CrossRefPubMedGoogle Scholar
  16. 16.
    Taylor K, Filgate R, Guo DY, Macneil F (2011) A retrospective study to assess the morbidity associated with transurethral prostatectomy in patients on antiplatelet or anticoagulant drugs. BJU Int 108:45–50CrossRefPubMedGoogle Scholar
  17. 17.
    Kuntz RM, Lehrich K, Ahyai SA (2008) Holmium laser enucleation of the prostate versus open prostatectomy for prostates greater than 100 grams: 5-year follow-up results of a randomised clinical trial. Eur Urol 53:160–166CrossRefPubMedGoogle Scholar
  18. 18.
    Gilling PJ, Wilson LC, King CJ et al (2012) Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years. BJU Int 109:408–411CrossRefPubMedGoogle Scholar
  19. 19.
    Sandhu JS, Ng CK, Gonzalez RR, Kaplan SA, Te AE (2005) Photoselective laser vaporization prostatectomy in men receiving anticoagulants. J Endourol 19:1196–1198CrossRefPubMedGoogle Scholar
  20. 20.
    Sohn JH, Choi YS, Kim SJ et al (2011) Effectiveness and safety of photoselective vaporization of the prostate with the 120 W HPS greenlight laser in benign prostatic hyperplasia patients taking oral anticoagulants. Korean J Urol 52:178–183CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Jaeger CD, Mitchell CR, Mynderse LA, Krambeck AE (2015) Holmium laser enucleation (HoLEP) and photoselective vaporisation of the prostate (PVP) for patients with benign prostatic hyperplasia (BPH) and chronic urinary retention. BJU Int 115:295–299CrossRefPubMedGoogle Scholar
  22. 22.
    Bishop CV, Liddell H, Ischia J et al (2013) Holmium laser enucleation of the prostate: comparison of immediate postoperative outcomes in patients with and without antithrombotic therapy. Curr Urol 7:28–33CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Mauri L, Kereiakes DJ, Yeh RW et al (2014) Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med 371:2155–2166CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Tanzilli G, Greco C, Pelliccia F et al (2009) Effectiveness of two-year clopidogrel + aspirin in abolishing the risk of very late thrombosis after drug-eluting stent implantation (from the TYCOON [two-year ClOpidOgrel need] study). Am J Cardiol 104:1357–1361CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Department of UrologyRenji Hospital affiliated to Shanghai Jiao Tong University, Medical SchoolShanghaiChina

Personalised recommendations